Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Earnings for Spero Therapeutics, Inc. (SPRO)
Earnings in 2023 (TTM): $25.4 M
According to Spero Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $25.4 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Spero Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $25.4 M | $22.81 M |
| 2022 | $-46,415,000 | $-48,028,000 |
| 2021 | $-89,756,000 | $-91,301,000 |
| 2020 | $-78,280,000 | $-77,519,000 |
| 2019 | $-60,925,000 | $-60,175,000 |
| 2018 | $-41,662,000 | $-41,662,000 |
| 2017 | $-46,097,000 | $-46,097,000 |
| 2016 | $-32,641,000 | $-25,491,000 |
| 2015 | $-13,153,000 | $-10,154,000 |